APIMEDS PHARMACEUTICALS US, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $105.21 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $105.21K, a 45.22% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $114.17K.
- APIMEDS PHARMACEUTICALS US, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $42.67K.
- APIMEDS PHARMACEUTICALS US, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $192.05K.
- APIMEDS PHARMACEUTICALS US, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $344.19K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|
| 2026-06-30 | $105.21K 10-Q · filed 2026-08-14 | $219.38K derived: sum of 2 quarters · filed 2026-08-14 | |
| 2026-03-31 | $114.17K 10-Q · filed 2026-08-14 | ||
| 2025-12-31 | $344.19K 10-K · filed 2026-05-04 | ||
| 2025-09-30 | $42.67K 10-Q · filed 2025-11-12 | $234.73K derived: sum of 2 quarters · filed 2026-08-14 | |
| 2025-06-30 | $192.05K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |